Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where authors phrase all words ' Canal, P' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 75 riferimenti
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Guichard, S; Montazeri, A; Chatelut, E; Hennebelle, I; Bugat, R; Canal, P
      Schedule-dependent activity of topotecan in OVCAR-3 ovarian carcinoma xenograft: Pharmacokinetic and pharmacodynamic evaluation

      CLINICAL CANCER RESEARCH
    2. Guichard, S; Arnould, S; Hennebelle, I; Bugat, R; Canal, P
      Combination of oxaliplatin and irinotecan on human colon cancer cell lines: activity in vitro and in vivo

      ANTI-CANCER DRUGS
    3. Patoux, A; Bleyzac, N; Boddy, AV; Doz, F; Rubie, H; Bastian, G; Maire, P; Canal, P; Chatelut, E
      Comparison of nonlinear mixed-effect and non-parametric expectation maximisation modelling for Bayesian estimation of carboplatin clearance in children

      EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
    4. Guichard, S; Canal, P
      New techniques and methods in cancer chemotherapy

      BULLETIN DU CANCER
    5. Chatelut, E; Pivot, X; Otto, J; Chevreau, C; Thyss, A; Renee, N; Milano, G; Canal, P
      A limited sampling strategy for determining carboplatin AUC and monitoringdrug dosage

      EUROPEAN JOURNAL OF CANCER
    6. Hennebelle, I; Terret, C; Chatelut, E; Bugat, R; Canal, P; Guichard, S
      Characterization of CPT-11 converting carboxylesterase activity in colon tumor and normal tissues: comparison with p-nitra-phenylacetate converting carboxylesterase activity

      ANTI-CANCER DRUGS
    7. Solary, E; Mannone, L; Moreau, D; Caillot, D; Casasnovas, RO; Guy, H; Grandjean, M; Wolf, JE; Andre, F; Fenaux, P; Canal, P; Chauffert, B; Wotawa, A; Bayssas, M; Gennes, P
      Phase I study of cinchonine, a multidrug resistance reversing agent, combined with the CHVP regimen in relapsed and refractory lymphoproliferative syndromes

      LEUKEMIA
    8. Fournet, A; Gilard, V; Malet-Martino, M; Martino, R; Canal, P; De Forni, M
      Stability of commercial solutions of 5-fluorouracil for continuous infusion in an ambulatory pump

      CANCER CHEMOTHERAPY AND PHARMACOLOGY
    9. Montazeri, A; Boucaud, M; Lokiec, F; Pinguet, F; Culine, S; Deporte-Fety, R; Albin, N; Laguerre, B; Goupil, A; Bugat, R; Canal, P; Chatelut, E
      Population pharmacokinetics of topotecan: intraindividual variability in total drug

      CANCER CHEMOTHERAPY AND PHARMACOLOGY
    10. Guimbaud, R; Guichard, S; Dusseau, C; Bertrand, V; Aparicio, T; Lochon, I; Chatelut, E; Couturier, D; Bugat, R; Chaussade, S; Canal, P
      Dihydropyrimidine dehydrogenase activity in normal, inflammatory and tumour tissues of colon and liver in humans

      CANCER CHEMOTHERAPY AND PHARMACOLOGY
    11. Canal, P; Kowalkowski, J; Maeshima, K; Yu, J; Wenzel, H; Snow, J; Arisawa, T; Ikado, K; Shimojima, M; Veramendi, G
      Online monitoring in the upcoming Fermilab Tevatron runII

      IEEE TRANSACTIONS ON NUCLEAR SCIENCE
    12. Terret, C; Erdociain, E; Guimbaud, R; Boisdron-Celle, M; McLeod, HL; Fety-Deporte, R; Lafont, T; Gamelin, E; Bugat, R; Canal, P; Chatelut, E
      Dose and time dependencies of 5-fluorouracil pharmacokinetics

      CLINICAL PHARMACOLOGY & THERAPEUTICS
    13. Chatelut, E; Canal, P; Bugat, R
      Pharmacokinetics and dose adjustment of carboplatin

      BULLETIN DU CANCER
    14. Canal, P
      Photosynthesis and 'inverse respiration' in plants: an inevitable misconception?

      INTERNATIONAL JOURNAL OF SCIENCE EDUCATION
    15. Perdaems, N; Caunes, N; Canal, P; Chatelut, E
      Possible excretion at etoposide via the intestinal mucosa

      CANCER CHEMOTHERAPY AND PHARMACOLOGY
    16. Tranchand, B; Amsellem, C; Chatelut, E; Freyer, G; Iliadis, A; Ligneau, B; Trillet-Lenoir, V; Canal, P; Lochon, I; Ardiet, CJ
      A limited-sampling strategy for estimation of etoposide pharmacokinetics in cancer patients

      CANCER CHEMOTHERAPY AND PHARMACOLOGY
    17. Chatelut, E; Rostaing, L; Gregoire, N; Payen, JL; Pujol, A; Izopet, J; Houin, G; Canal, P
      A pharmacokinetic model for alpha interferon administered subcutaneously

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    18. Gladieff, L; Chatelut, E; Gaspard, MH; Skaf, R; de Forni, M; Mihura, J; Canal, P; Bugat, R
      Intraperitoneal high dose chemotherapy as consolidation treatment for advanced ovarian carcinoma: a pilot study

      BULLETIN DU CANCER
    19. Canal, P; Gautie, L; Gregoire, N; Perdaems, N; Chatelut, E
      News on the pharmacokinetics of anticancer drags

      BULLETIN DU CANCER
    20. Guichard, S; Terret, C; Hennebelle, I; Lochon, I; Chevreau, P; Fretigny, E; Selves, J; Chatelut, E; Bugat, R; Canal, P
      CPT-11 converting carboxylesterase and topoisomerase I activities in tumour and normal colon and liver tissues

      BRITISH JOURNAL OF CANCER
    21. Simeon, N; Chatelut, E; Canal, P; Nertz, M; Couderc, F
      Anthracycline analysis by capillary electrophoresis - Application to the analysis of daunorubicine in Kaposi sarcoma tumor

      JOURNAL OF CHROMATOGRAPHY A
    22. ROSTAING L; CHATELUT E; PAYEN JL; IZOPET J; THALAMAS C; TONTHAT H; PASCAL JP; DURAND D; CANAL P
      PHARMACOKINETICS OF ALPHA-IFN-2B IN CHRONIC HEPATITIS-C VIRUS PATIENTS UNDERGOING CHRONIC-HEMODIALYSIS OR WITH NORMAL RENAL-FUNCTION - CLINICAL IMPLICATIONS

      Journal of the American Society of Nephrology
    23. ETIENNE MC; CHATELUT E; PIVOT X; LAVIT M; PUJOL A; CANAL P; MILANO G
      CO-VARIABLES INFLUENCING 5-FLUOROURACIL CLEARANCE DURING CONTINUOUS VENOUS INFUSION - A NONMEM ANALYSIS

      European journal of cancer
    24. BEKRADDA M; CHATELUT E; CVITKOVIC E; SOULIE P; CANAL P; MISSET JL; DUPONTANDRE G; BENSMAINE MA; BUGAT R
      PHARMACOKINETICS (PK) AND PHARMACODYNAMICS OF THE CARBOPLATIN (CBDCA)OXALIPLATIN (L-OHP) COMBINATION IN PATIENTS (PTS) WITH ADVANCED MALIGNANCIES - PRELIMINARY-RESULTS OF AN ONGOING PHASE-I TRIAL/

      Annals of oncology
    25. DOZ F; URIEN S; CHATELUT E; MICHON J; RUBIE H; ZUCKER JM; CANAL P; BASTIAN G
      A LIMITED-SAMPLING METHOD FOR EVALUATION OF THE AREA-UNDER-THE-CURVE OF ULTRAFILTERABLE CARBOPLATIN IN CHILDREN

      Cancer chemotherapy and pharmacology
    26. GUICHARD S; CHATELUT E; LOCHON I; BUGAT R; MAHJOUBI M; CANAL P
      COMPARISON OF THE PHARMACOKINETICS AND EFFICACY OF IRINOTECAN AFTER ADMINISTRATION BY THE INTRAVENOUS VERSUS INTRAPERITONEAL ROUTE IN MICE

      Cancer chemotherapy and pharmacology
    27. NGUYEN L; CHATELUT E; CHEVREAU C; TRANCHAND B; LOCHON I; BACHAUD JM; PUJOL A; HOUIN G; BUGAT R; CANAL P
      POPULATION PHARMACOKINETICS OF TOTAL AND UNBOUND ETOPOSIDE

      Cancer chemotherapy and pharmacology
    28. JOQUEVIEL C; MARTINO R; GILARD V; MALETMARTINO M; CANAL P; NIEMEYER U
      URINARY-EXCRETION OF CYCLOPHOSPHAMIDE IN HUMANS, DETERMINED BY P-31 NUCLEAR-MAGNETIC-RESONANCE SPECTROSCOPY

      Drug metabolism and disposition
    29. MONSARRAT B; CHATELUT E; ROYER I; ALVINERIE P; DUBOIS J; DEZEUSE A; ROCHE H; CROS S; WRIGHT M; CANAL P
      MODIFICATION OF PACLITAXEL METABOLISM IN A CANCER-PATIENT BY INDUCTION OF CYTOCHROME-P450 3A4

      Drug metabolism and disposition
    30. Perdaems, N; Bachaud, JM; Rouzaud, P; Murris-Espin, M; Hermant, C; Mihura, J; Lochon, I; Houin, G; Canal, P; Chatelut, E
      Relation between unbound plasma concentrations and toxicity in a prolongedoral etoposide schedule

      EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
    31. GUIMBAUD R; GUICHARD S; BERTRAND V; APARICIO T; TERRET C; BUGAT R; COUTURIER D; CHATELUT E; CANAL P; CHAUSSADE S
      VARIABILITY OF DIHYDROPYRIMIDINE DESHYDROGENASE (DPD) ACTIVITY IN NORMAL, INFLAMMATORY AND TUMORAL TISSUES OF COLON AND LIVER IN HUMANS

      Gastroenterology
    32. Canal, P; Chatelut, E; Guichard, S
      Practical treatment guide for dose individualisation in cancer chemotherapy

      DRUGS
    33. MARTIN L; CHATELUT E; BONEU A; ROSTAING L; ROUSSILHES C; CASELLES O; CANAL P
      IMPROVEMENT OF THE COCKCROFT-GAULT EQUATION FOR PREDICTING GLOMERULAR-FILTRATION IN CANCER-PATIENTS

      Bulletin du cancer
    34. Gautie, L; Canal, P; Menguy, A; Latour, JF; Benard, I; Courbard, M; Brunelle, P; Carpentier, Y; Pinguet, F; Chevrier, R; Doly, M; Watelet, M; Briere, M; Viau, P; Duban, M; German, O; Gosselin, P; de La Jarrige, PL; Bertrand, C; Pommier, M; Prebay, D
      Analysis of medical prescription of granulocyte-colony stimulating factorsin 19 French anticancer centers

      BULLETIN DU CANCER
    35. Chabot, GG; Robert, J; Lokiec, F; Canal, P
      Irinotecan pharmacokinetics

      BULLETIN DU CANCER
    36. GUICHARD S; HENNEBELLE I; BUGAT R; CANAL P
      CELLULAR INTERACTIONS OF 5-FLUOROURACIL AND THE CAMPTOTHECIN ANALOG CPT-11 (IRINOTECAN) IN A HUMAN COLORECTAL-CARCINOMA CELL-LINE

      Biochemical pharmacology
    37. RIVORY LP; HAAZ MC; CANAL P; LOKIEC F; ARMAND JP; ROBERT J
      PHARMACOKINETIC INTERRELATIONSHIPS OF IRINOTECAN (CPT-11) AND ITS 3 MAJOR PLASMA METABOLITES IN PATIENTS ENROLLED IN PHASE-I II TRIALS/

      Clinical cancer research
    38. GUIMBAUD R; BUGAT R; VANCUTSEM E; MIGNARD D; MAHJOUBI M; CANAL P; BLANC C
      CONSISTENT SAFETY AND EFFICACY RESULTS IN 2 STUDY POPULATIONS TREATEDWITH IRINOTECAN (CPT-11) FOR METASTATIC COLORECTAL-CANCER (MCRC) RESISTANT TO 5-FU

      European journal of cancer
    39. BENEZET S; CHATELUT E; GUIMBAUD R; CHEVREAU C; BUGAT R; CANAL P
      IS CHATELUT FORMULA APPLICABLE IN OBESE PATIENTS FOR PREDICTING CARBOPLATIN CLEARANCE

      European journal of cancer
    40. BENEZET S; GUIMBAUD R; CHATELUT E; CHEVREAU C; BUGAT R; CANAL P
      HOW TO PREDICT CARBOPLATIN CLEARANCE FROM STANDARD MORPHOLOGICAL AND BIOLOGICAL CHARACTERISTICS IN OBESE PATIENTS

      Annals of oncology
    41. BACHAUD JM; CHATELUT E; CANAL P; ALBIN N; YARDENI E; DAVID JM; SERRANO E; DALYSCHVEITZER N
      RADIOTHERAPY WITH CONCOMITANT CONTINUOUS CISPLATIN INFUSION FOR UNRESECTABLE TUMORS OF THE UPPER AERODIGESTIVE TRACT - RESULTS OF A PHASE-ISTUDY

      American journal of clinical oncology
    42. PINGUET F; MARTEL P; FABBRO M; PETIT I; CANAL P; CULINE S; ASTRE C; BRESSOLLE F
      PHARMACOKINETICS OF HIGH-DOSE INTRAVENOUS MELPHALAN IN PATIENTS UNDERGOING PERIPHERAL-BLOOD HEMATOPOIETIC PROGENITOR-CELL TRANSPLANTATION

      Anticancer research
    43. GUICHARD S; CUSSAC D; HENNEBELLE I; BUGAT R; CANAL P
      SEQUENCE-DEPENDENT ACTIVITY OF THE IRINOTECAN-5FU COMBINATION IN HUMAN COLON-CANCER MODEL HT-29 IN-VITRO AND IN-VIVO

      International journal of cancer
    44. BENEZET S; CHATELUT E; BAGHERI H; RIGALHUGUET F; NGUYEN L; POURRAT J; ROBERT A; MONTASTRUC JL; CANAL P
      INEFFICACY OF EXCHANGE-TRANSFUSION IN A METHOTREXATE INTOXICATION

      Bulletin du cancer
    45. EVENE E; CHATELUT E; TRANCHAND B; CANAL P; LOCHON I; ILIADIS A; ARDIET CJ
      BAYESIAN-ESTIMATION OF ETOPOSIDE PHARMACO KINETIC PARAMETERS

      Bulletin du cancer
    46. CALIARO MJ; VITAUX P; LAFON C; LOCHON I; NEHME A; VALETTE A; CANAL P; BUGAT R; JOZAN S
      MULTIFACTORIAL MECHANISM FOR THE POTENTIATION OF CISPLATIN (CDDP) CYTOTOXICITY BY ALL-TRANS-RETINOIC ACID (ATRA) IN HUMAN OVARIAN-CARCINOMACELL-LINES

      British Journal of Cancer
    47. CHATELUT E; CHEVREAU C; CANAL P
      PREDICTION OF CARBOPLATIN CLEARANCE FROM STANDARD MORPHOLOGICAL AND BIOLOGICAL PATIENT CHARACTERISTICS - RESPONSE

      Journal of the National Cancer Institute
    48. CANAL P; GAY C; DEZEUZE A; DOUILLARD JY; BUGAT R; BRUNET R; ADENIS A; HERAIT P; LOKIEC F; MATHIEUBOUE A
      PHARMACOKINETICS AND PHARMACODYNAMICS OF IRINOTECAN DURING A PHASE-IICLINICAL-TRIAL IN COLORECTAL-CANCER

      Journal of clinical oncology
    49. CHATELUT E; BODDY AV; PENG B; RUBIE H; LAVIT M; DEZEUZE A; PEARSON ADJ; ROCHE H; ROBERT A; NEWELL DR; CANAL P
      POPULATION PHARMACOKINETICS OF CARBOPLATIN IN CHILDREN

      Clinical pharmacology and therapeutics
    50. CANAL P; CHATELUT E
      DOSE OPTIMIZATION IN CLINICAL ONCOLOGY - PHARMACOKINETIC-PHARMACODYNAMIC RELATIONSHIPS

      Bulletin du cancer
    51. LOKIEC F; CANAL P; MATHIEUBOUE A; ARMAND JP; BUGAT R
      CPT-11 METABOLISM IN BLOOD, BILE AND URINE IN CANCER-PATIENTS

      European journal of cancer
    52. RIVORY LP; CANAL P; MATHIEUBOUE A; ROBERT J
      PHARMACOKINETICS AND INTERCONVERSION OF THE CARBOXYLATE AND LACTONE FORMS OF IRINOTECAN (CPT-11) AND OF ITS METABOLITE SN-38 IN PATIENTS

      European journal of cancer
    53. LOKIEC F; CANAL P; GAY C; CHATELUT E; ARMAND JP; ROCHE H; BUGAT R; GONCALVES E; MATHIEUBOUE A
      PHARMACOKINETICS OF IRINOTECAN AND ITS METABOLITES IN HUMAN BLOOD, BILE, AND URINE

      Cancer chemotherapy and pharmacology
    54. CHATELUT E; CHEVREAU C; BRUNNER V; MARTINEZ M; HOUIN G; BUGAT R; CANAL P
      A PHARMACOLOGICALLY GUIDED PHASE-I STUDY OF CARBOPLATIN COMBINATION WITH METHOTREXATE AND VINBLASTINE IN ADVANCED UROTHELIAL CANCER

      Cancer chemotherapy and pharmacology
    55. BRUNNER V; HOUYAU P; CHATELUT E; ROCHE H; CANAL P
      CEREBROSPINAL-FLUID CONCENTRATIONS OF CARBOPLATIN IN A PATIENT WITHOUT BLOOD-BRAIN-BARRIER DISRUPTION

      Cancer chemotherapy and pharmacology
    56. NEHME A; ALBIN N; CALIARO MJ; GUICHARD S; JOZAN S; JULIA AM; BUGAT R; CANAL P
      MECHANISM OF INTERACTION BETWEEN CISPLATIN AND HUMAN RECOMBINANT INTERFERON-GAMMA IN HUMAN OVARIAN-CANCER CELL-LINES

      International journal of cancer
    57. LAVIT M; CHEVREAU C; CHATELUT E; DEFENIN V; LOCHON I; HOUIN G; BUGAT R; CANAL P
      RELATIONSHIPS BETWEEN HEMATOLOGICAL TOXIC ITY AND TOTAL AND FREE ETOPOSIDE PLASMATIC LEVELS WITH DAILY ORAL ETOPOSIDE ADMINISTRATION

      Bulletin du cancer
    58. CHATELUT E; DEZEUZE A; LAVIT M; CHEVREAU C; PUJOL A; BONEU A; ROCHE H; HOUIN G; BUGAT R; CANAL P
      PREDICTION OF CARBOPLATINE CLEARANCE FROM MORPHOLOGICAL AND BIOLOGICAL PATIENT CHARACTERISTICS

      Bulletin du cancer
    59. NOUADJE G; RUBIE H; CHATELUT E; CANAL P; NERTZ M; PUIG P; COUDERC F
      CHILD CEREBROSPINAL-FLUID ANALYSIS BY CAPILLARY ELECTROPHORESIS AND LASER-INDUCED FLUORESCENCE DETECTION

      Journal of chromatography
    60. CHATELUT E; CANAL P; BRUNNER V; CHEVREAU C; PUJOL A; BONEU A; ROCHE H; HOUIN G; BUGAT R
      PREDICTION OF CARBOPLATIN CLEARANCE FROM STANDARD MORPHOLOGICAL AND BIOLOGICAL PATIENT CHARACTERISTICS

      Journal of the National Cancer Institute
    61. NEHME A; JULIA AM; JOZAN S; CHEVREAU C; BUGAT R; CANAL P
      MODULATION OF CISPLATIN CYTOTOXICITY BY HUMAN RECOMBINANT INTERFERON-GAMMA IN HUMAN OVARIAN-CANCER CELL-LINES

      European journal of cancer
    62. ATTAL M; CANAL P; SCHLAIFER D; CHATELUT E; DEZEUZE A; HUGUET F; PAYEN C; PRIS J; LAURENT G
      ESCALATING DOSE OF MITOXANTRONE WITH HIGH-DOSE CYCLOPHOSPHAMIDE, CARMUSTINE, AND ETOPOSIDE IN PATIENTS WITH REFRACTORY LYMPHOMA UNDERGOING AUTOLOGOUS BONE-MARROW TRANSPLANTATION

      Journal of clinical oncology
    63. SCHLAIFER D; ATTAL M; HUGUET F; CANAL P; LAURENT G; PRIS J
      ESCALATING DOSE OF MITOXANTRONE WITH HIGH-DOSE CYCLOPHOSPHAMIDE, CARMUSTINE, AND ETOPOSIDE IN REFRACTORY LYMPHOMA PATIENTS UNDERGOING AUTOLOGOUS BONE-MARROW TRANSPLANTATION

      Seminars in hematology
    64. ATTAL M; CANAL P; SCHLAIFER D; PRIS J; LAURENT G
      SIGNIFICANCE OF HIGH-DOSAGE MITOXANTRONE IN MANAGEMENT OF MALIGNANT-LYMPHOMAS

      Nouvelle revue francaise d'hematologie
    65. CHATELUT E; ROSTAING L; GUALANO V; VISSAC T; DEFORNI M; TONTHAT H; SUC JM; HOUIN G; CANAL P
      PHARMACOKINETICS OF CARBOPLATIN IN A PATIENT SUFFERING FROM ADVANCED OVARIAN-CARCINOMA WITH HEMODIALYSIS-DEPENDENT PENAL INSUFFICIENCY

      Nephron
    66. RIVORY LP; CHATELUT E; CANAL P; MATHIEUBOUE A; ROBERT J
      KINETICS OF THE IN-VIVO INTERCONVERSION OF THE CARBOXYLATE AND LACTONE FORMS OF IRINOTECAN (CPT-11) AND OF ITS METABOLITE SN-38 IN PATIENTS

      Cancer research
    67. BACHAUD JM; ALBIN N; GAY C; CHATELUT E; BENCHALAL M; DAVID JM; BONEU A; SERRANO E; CANAL P; DALYSCHVEITZER N
      CONCOMITANT RADIOCHEMOTHERAPY (CDDP 4-6 M G M2/D) IN LOCALLY ADVANCEDHEAD AND NECK-CANCER/

      Bulletin du cancer
    68. NEHME A; ALBIN N; JULIA AM; JOZAN S; BUGAT R; CANAL P
      MECHANISMS OF INTERACTION BETWEEN CISPLAT IN AND HUMAN RECOMBINANT INTERFERON-GAMMA (INF-GAMMA) IN HUMAN OVARIAN-CANCER CELL-LINES

      Bulletin du cancer
    69. JULIA AM; ROCHE H; BERLION M; LUCAS C; MILANO G; ROBERT J; BIZZARI JP; CANAL P
      MULTIDRUG-RESISTANCE CIRCUMVENTION HY A NEW TRIAZINOAMINOPIPERIDINE DERIVATIVE S9788 IN-VITRO - DEFINITION OF THE OPTIMAL SCHEDULE AND COMPARISON WITH VERAPAMIL

      British Journal of Cancer
    70. MULLER C; CHATELUT E; GUALANO V; DEFORNI M; HUGUET F; ATTAL M; CANAL P; LAURENT G
      CELLULAR PHARMACOKINETICS OF DOXORUBICIN IN PATIENTS WITH CHRONIC LYMPHOCYTIC-LEUKEMIA - COMPARISON OF BOLUS ADMINISTRATION AND CONTINUOUS-INFUSION

      Cancer chemotherapy and pharmacology
    71. ROCHE H; JULIA AM; JOZAN S; MULLER C; DASTUGUE N; ARQUIER MA; MARQUES B; LAURENT G; CANAL P
      CHARACTERIZATION AND CHEMOSENSITIVITY OF A HUMAN EPITHELIOID SARCOMA CELL-LINE (SARCCR-2)

      International journal of cancer
    72. CANAL P; ATTAL M; CHATELUT E; GUICHARD S; HUGUET F; MULLER C; SCHLAIFER D; LAURENT G; HOUIN G; BUGAT R
      PLASMA AND CELLULAR PHARMACOKINETICS OF MITOXANTRONE IN HIGH-DOSE CHEMOTHERAPEUTIC REGIMEN FOR REFRACTORY LYMPHOMAS

      Cancer research
    73. DEFORNI M; GUALANO V; CANAL P; MARTEL P; IZARSOUM F; CHEVREAU C; SOULIE P; ROCHE H; BUGAT R
      CONTINUOUS-INFUSION OF 5-FLUOROURACIL BY DOUBLE ROUTE (INTRAVENOUS AND INTRAPERITONEAL) WITH MODULATION BY FOLINIC ACID - CLINICAL AND PHARMACOKINETIC, PHASE-I STUDY IN PATIENTS WITH INTRAABDOMINAL MALIGNANCIES

      Bulletin du cancer
    74. SAMADIBABOLI M; FAVRE G; CANAL P; SOULA G
      LOW-DENSITY-LIPOPROTEIN FOR CYTOTOXIC DRUG TARGETING - IMPROVED ACTIVITY OF ELLIPTINIUM DERIVATIVE AGAINST B16 MELANOMA IN MICE

      British Journal of Cancer
    75. HOUYAU P; GAY C; CHATELUT E; CANAL P; ROCHE H; MILANO G
      SEVERE FLUOROURACIL TOXICITY IN A PATIENT WITH DIHYDROPYRIMIDINE DEHYDROGENASE-DEFICIENCY

      Journal of the National Cancer Institute


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 15/01/21 alle ore 23:15:30